Whereas the chemopreventive potential of AHR antagonists against PAH-induced skin cancers is mainly due to a decrease in CYP1A enzyme activity and associated metabolic activation, these compounds may alter ECM remodeling, DNA repair and apoptosis to prevent or delay skin wrinkling and photocarcinogenesis. The gene discussed is AHR; the disease is skin neoplasm.